These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 27710139)

  • 21. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
    Os I; Franco V; Kjeldsen SE; Manhem K; Devereux RB; Gerdts E; Hille DA; Lyle PA; Okin PM; Dahlöf B; Oparil S
    Hypertension; 2008 Apr; 51(4):1103-8. PubMed ID: 18259029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
    Oikarinen L; Nieminen MS; Viitasalo M; Toivonen L; Jern S; Dahlöf B; Devereux RB; Okin PM;
    Hypertension; 2004 May; 43(5):1029-34. PubMed ID: 15037560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
    Kizer JR; Dahlöf B; Kjeldsen SE; Julius S; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Wachtell K; Edelman JM; Snapinn SM; Harris KE; Devereux RB
    Hypertension; 2005 Jan; 45(1):46-52. PubMed ID: 15583076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of overweight and obesity on cardiac benefit of antihypertensive treatment.
    Gerdts E; de Simone G; Lund BP; Okin PM; Wachtell K; Boman K; Nieminen MS; Dahlöf B; Devereux RB
    Nutr Metab Cardiovasc Dis; 2013 Feb; 23(2):122-9. PubMed ID: 21775111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
    Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Dahlöf B;
    Ann Intern Med; 2007 Sep; 147(5):311-9. PubMed ID: 17785486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study.
    Cicala S; de Simone G; Wachtell K; Gerdts E; Boman K; Nieminen MS; Dahlöf B; Devereux RB
    J Hypertens; 2008 Apr; 26(4):806-12. PubMed ID: 18327092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
    Søraas CL; Wachtell K; Okin PM; Dahlöf B; Devereux RB; Tønnessen T; Kjeldsen SE; Olsen MH
    Blood Press; 2010 Jun; 19(3):145-51. PubMed ID: 20429689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy.
    Okin PM; Kamel H; Kjeldsen SE; Devereux RB
    J Hypertens; 2016 Sep; 34(9):1831-7. PubMed ID: 27254312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM
    J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study).
    Gerdts E; Cramariuc D; de Simone G; Wachtell K; Dahlöf B; Devereux RB
    Eur J Echocardiogr; 2008 Nov; 9(6):809-15. PubMed ID: 18490279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients.
    Okin PM; Devereux RB; Nieminen MS; Jern S; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Julius S; Snapinn S; Dahlöf B;
    Hypertension; 2004 Jul; 44(1):48-54. PubMed ID: 15173125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
    J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-treatment stroke volume predicts cardiovascular risk in hypertension.
    Lønnebakken MT; Gerdts E; Boman K; Wachtell K; Dahlöf B; Devereux RB
    J Hypertens; 2011 Aug; 29(8):1508-14. PubMed ID: 21720264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic impact of increased pulse pressure/stroke index in a registry of hypertensive patients: the Campania Salute Network.
    Mancusi C; Losi MA; Izzo R; Gerdts E; Canciello G; Arnone MI; Trimarco B; de Simone G; De Luca N
    Blood Press; 2019 Aug; 28(4):268-275. PubMed ID: 31068016
    [No Abstract]   [Full Text] [Related]  

  • 35. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
    Wachtell K; Okin PM; Olsen MH; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Nieminen MS; Thygesen K
    Circulation; 2007 Aug; 116(7):700-5. PubMed ID: 17664372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
    Okin PM; Kjeldsen SE; Julius S; Hille DA; Dahlöf B; Edelman JM; Devereux RB
    Eur Heart J; 2010 Sep; 31(18):2271-9. PubMed ID: 20601389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
    Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
    Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
    Gerdts E; Wachtell K; Omvik P; Otterstad JE; Oikarinen L; Boman K; Dahlöf B; Devereux RB
    Hypertension; 2007 Feb; 49(2):311-6. PubMed ID: 17178978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study).
    Gerdts E; Papademetriou V; Palmieri V; Boman K; Björnstad H; Wachtell K; Giles TD; Dahlöf B; Devereux RB;
    Am J Cardiol; 2002 Feb; 89(4):399-402. PubMed ID: 11835919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.